A Study of Nilotinib Versus Imatinib in GIST Patients

NCT00785785 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

644

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Stromal Tumor (GIST)

Interventions

DRUG: Nilotinib (AMN107)
DRUG: imatinib (STI571)

Sponsor

Novartis Pharmaceuticals